RIP1-IN-1
RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (Kd: 110 nM) . RIP1-IN-1 exhibits strong anti-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury[1].
Product Specifications
UNSPSC
12352005
Target
Necroptosis; RIP kinase
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
CN1C2=CC=CC=C2OC[C@H](NC(C3=CC(C(C4=CC=CC=C4)=CC=N5)=C5C=C3)=O)C1=O
Molecular Formula
C26H21N3O3
Molecular Weight
423.46
References & Citations
[1]Xu B, et al. Discovery of a novel quinoline RIP1 inhibitor and its treatment of acute liver injury in mice. Bioorg Chem. 2025 Mar 12;159:108365.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RIPK1
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
NAPSA (NAP1, NAPA, Napsin-A, Aspartyl Protease 4, ASP4, Asp 4, Napsin-1, TA01/TA02) APC
NAPSA (NAP1, NAPA, Napsin-A, Aspartyl Protease 4, ASP4, Asp 4, Napsin-1, TA01/TA02) APC
